Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

• Status: Completed
• Trial end date: 2012-02-01

Summary

This study is to assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171)in combination with etoposide and cisplatin (EP) as first line treatment for lung cancer patients with extensive stage or metastatic disease for whom EP would be a standard therapy.

• Phase: Phase 1

Details

• Lead Sponsor: AstraZeneca
• Treatments: Cediranib; Cisplatin; Etoposide; Etoposide phosphate